Posts

Milestone plans 20% workforce cut as CFO and CMO depart

Milestone Pharmaceuticals announced a workforce reduction of about 20%, expected to be completed by the first quarter of 2027. The company says broader efficiency measures are intended to lower operating expenses by roughly 30%. CFO Amit Hasija resigned effective November 13, 2026. VP of Finance Anthony Krick is serving as principal financial and accounting officer while the company searches for a replacement CFO. CMO David Bharucha’s role ended November 12 as part of the restructuring; he is transitioning to a consulting/advisory role with the company. The cuts aim to extend Milestone’s cash runway into late 2028 as it develops its heart-rhythm treatment CARDAMYST and advances clinical work. The company expects about $2 million in one-time restructuring-related costs. CARDAMYST generated $1 million in Q3 sales, up 73% from the prior quarter. The company reported a $25.8 million quarterly net loss, underscoring the financial pressure behind the cost reductions. Sources: Mil...

FDA rejects ivonescimab for a narrow lung cancer indication

QRL-201 FDA IND clearance: headline not confirmed by available results

HHS backs ibogaine development and broader psychedelic research

Regeneron’s baloncibart shows Phase 2 promise in POTS

Windward raises $225M with Sanofi support as Rezera postpones IPO

Bavarian Nordic beats Q3 revenue estimates as CFO announces planned 2027 departure

FDA’s speedy voucher program reportedly shelved, but HHS says pilot is ongoing

Vir Biotechnology prices $150 million stock offering

Unlearn and Structure to explore AI digital twins in obesity study

Q3 2026 earnings-season losers: sharp drops and disappointing outlooks

Astellas and Immuneering plan two pancreatic cancer studies

FDA reportedly shelves speedy drug-review voucher program